APA

Zhuang Y., Calderon C., Marciniak S. J., Bouman-Thio E., Szapary P., Yang T., Schantz A., Davis H. M., Zhou H. & Xu Z. (20170223). First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. : European journal of clinical pharmacology.

Chicago

Zhuang Yanli, Calderon Cesar, Marciniak Stanley J, Bouman-Thio Esther, Szapary Philippe, Yang Tong-Yuan, Schantz Allen, Davis Hugh M, Zhou Honghui and Xu Zhenhua. 20170223. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. : European journal of clinical pharmacology.

Harvard

Zhuang Y., Calderon C., Marciniak S. J., Bouman-Thio E., Szapary P., Yang T., Schantz A., Davis H. M., Zhou H. and Xu Z. (20170223). First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. : European journal of clinical pharmacology.

MLA

Zhuang Yanli, Calderon Cesar, Marciniak Stanley J, Bouman-Thio Esther, Szapary Philippe, Yang Tong-Yuan, Schantz Allen, Davis Hugh M, Zhou Honghui and Xu Zhenhua. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. : European journal of clinical pharmacology. 20170223.